Covid 19 Research using Clinical Trials (Home Page)
HP:0002621: AtherosclerosisHPO
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug579 | CPI-006 Wiki | 0.71 |
| drug1739 | Metformin XR Wiki | 0.71 |
| drug580 | CRI management Wiki | 0.71 |
| drug1374 | Icosapent ethyl Wiki | 0.50 |
| drug2122 | Placebo Wiki | 0.04 |
Correlated MeSH Terms (4)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D050197 | Atherosclerosis NIH | 1.00 |
| D011236 | Prediabetic State NIH | 0.50 |
| D012141 | Respiratory Tract Infections NIH | 0.14 |
| D002318 | Cardiovascular Diseases NIH | 0.13 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011947 | Respiratory tract infection HPO | 0.14 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.13 |
There are 2 clinical trials
Clinical Trials
1 CSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT)
This research will help us to learn if the medicine called metformin reduces the risk of death, heart attacks, and/or strokes in patients who have pre-diabetes and heart or blood vessel problems.
NCT02915198 Prediabetic State Atherosclerosis Metformin Drug: Metformin XR Drug: Placebo MeSH:Atherosclerosis Prediabetic State
HPO:Atherosclerosis Type IV atherosclerotic lesion
Primary Outcomes
Description: The primary outcome measure is the time to first occurrence of death, non-fatal myocardial infarction or stroke, hospitalization for unstable angina with objective evidence of acute myocardial ischemia, or coronary revascularization driven by acute or progressive symptoms.
Measure: Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization Time: through study completion, an average of 4.5 years
Secondary Outcomes
Description: Time to first occurrence of death, myocardial infarction, or stroke
Time to first occurrence of a primary endpoint event, peripheral arterial disease event, or hospitalization for congestive heart failure
Cumulative incidence of all components of the primary endpoint, including recurrent or multiple events in the same participant
Cumulative incidence and time to first occurrence of each component of the primary outcome measure, peripheral arterial disease events, and hospitalization for congestive heart failure
Measure: Time in days to Cardiovascular Outcomes Time: through study completion, an average of 4.5 years
Description: Time to new or recurrent diagnosis of a malignancy or death from a malignancy
Measure: Time in days to Oncologic Outcome Time: through study completion, an average of 4.5 years
Description: Time to new diagnosis of type 2 diabetes (ADA criteria)
Measure: Time in days to Diabetes Outcome Time: through study completion, an average of 4.5 years
2 A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults in the Era of Coronavirus Disease 2019 (MITIGATE COVID-19)
Primary Outcomes
Description: The primary outcome measure is the time to first occurrence of death, non-fatal myocardial infarction or stroke, hospitalization for unstable angina with objective evidence of acute myocardial ischemia, or coronary revascularization driven by acute or progressive symptoms.
Measure: Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization Time: through study completion, an average of 4.5 yearsSecondary Outcomes
Description: Time to first occurrence of death, myocardial infarction, or stroke Time to first occurrence of a primary endpoint event, peripheral arterial disease event, or hospitalization for congestive heart failure Cumulative incidence of all components of the primary endpoint, including recurrent or multiple events in the same participant Cumulative incidence and time to first occurrence of each component of the primary outcome measure, peripheral arterial disease events, and hospitalization for congestive heart failure
Measure: Time in days to Cardiovascular Outcomes Time: through study completion, an average of 4.5 yearsDescription: Time to new or recurrent diagnosis of a malignancy or death from a malignancy
Measure: Time in days to Oncologic Outcome Time: through study completion, an average of 4.5 yearsDescription: Time to new diagnosis of type 2 diabetes (ADA criteria)
Measure: Time in days to Diabetes Outcome Time: through study completion, an average of 4.5 yearsMITIGATE COVID-19 is a prospective, open-label, parallel-group, randomized, pragmatic clinical trial. The MITIGATE COVID-19 Study has been designed to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), also known as Vascepa®, compared to usual standard of care to prevent and reduce the sequelae of laboratory-confirmed viral upper respiratory infection (URI)-related (i.e., COVID-19, influenza, and other known viral respiratory pathogens) morbidity and mortality in a high-risk cohort of adults with established atherosclerotic cardiovascular disease (ASCVD).
NCT04505098 Covid19 Atherosclerosis Cardiovascular Diseases Upper Respiratory Tract Infections Drug: Icosapent ethyl MeSH:Respiratory Tract Infections Atherosclerosis Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system Atherosclerosis Respiratory tract infection Type IV atherosclerotic lesion
Primary Outcomes
Description: Confirmed viral URIs (i.e., including recurrent events) (i.e., COVID-19, influenza, and other known viral respiratory pathogens) based on laboratory testing (i.e., FDA or locally-approved testing modalities) with an oxygen saturation <94% on room air and/or requiring any form of supplemental oxygen.
Measure: Percentage of patients with moderate or severe confirmed viral URIs Time: 0-12 months
Description: At any point in time based on a 7-point ordinal scale (i.e., 1 = death, 2 = mechanically ventilated/extracorporeal membrane oxygenation, 3 = high flow supplemental oxygen, 4 = low flow supplemental oxygen, 5 = hospitalized with no supplemental oxygen requirements, 6 = urgent care or emergency department visit not leading to hospitalization, and 7 = no relevant clinical encounters)
Measure: Worst clinical status due to a confirmed viral URI Time: 0-12 months
Other Outcomes
Measure: Percentage of participants who die due to any cause Time: 0-12 months
Description: Death due to any cause, hospitalization for myocardial infarction, or hospitalization for ischemic stroke
Measure: Percentage of participants experiencing a major adverse cardiovascular event Time: 0-12 months
Description: Major adverse cardiovascular events, hospitalization for acute coronary syndrome, and coronary revascularization (i.e., percutaneous coronary intervention and/or coronary artery bypass graft)
Measure: Percentage of participants experiencing an expanded major adverse cardiovascular event Time: 0-12 months
Measure: Percentage of participants who are hospitalized for heart failure Time: 0-12 months
Measure: Percentage of participants who are hospitalized for any reason Time: 0-12 months
Measure: Percentage of participants who have an emergency department visit for any reason Time: 0-12 months
HPO Nodes
HP:0002621: Atherosclerosis
Genes 90
ZNF687 CYP27A1 BSCL2 GGCX ACTA2 NPC2 SERPIND1 LOX ENG KCNJ5 LDLR SMAD4 LMNA ESR1 GGCX SC5D PRKG1 SMPD1 ABCA1 WRN LCAT CSF2RB SMAD3 ABCC6 NOTCH3 MFAP5 TGFBR3 SMPD1 CYP7A1 ABCG8 LMNA ACTA2 ABCA1 CEP19 ALMS1 CAV1 LMNA APOA5 LOX TGFBR2 ELN APOE XYLT1 ABCA1 LDLRAP1 MYLK ABCC6 TGFB3 BANF1 LMNA ANGPTL6 PCSK9 ENPP1 LDLRAP1 CSF2RA FOS APOB TNXB APOB MAT2A FBN1 PPARG ZMPSTE24 LMNA LMNA AGXT COL3A1 LMNA AGPAT2 TGFBR1 TGFB2 ABCG5 GLB1 SMPD1 LMNA XYLT2 FOXE3 THSD1 MYH11 PPARG ANTXR1 MYH11 CAVIN1 LIPC ABCG8 MYH11 NPC1 LCAT ASAH1 HGD
Primary Outcomes
Description: Confirmed viral URIs (i.e., including recurrent events) (i.e., COVID-19, influenza, and other known viral respiratory pathogens) based on laboratory testing (i.e., FDA or locally-approved testing modalities) with an oxygen saturation <94% on room air and/or requiring any form of supplemental oxygen.
Measure: Percentage of patients with moderate or severe confirmed viral URIs Time: 0-12 monthsDescription: At any point in time based on a 7-point ordinal scale (i.e., 1 = death, 2 = mechanically ventilated/extracorporeal membrane oxygenation, 3 = high flow supplemental oxygen, 4 = low flow supplemental oxygen, 5 = hospitalized with no supplemental oxygen requirements, 6 = urgent care or emergency department visit not leading to hospitalization, and 7 = no relevant clinical encounters)
Measure: Worst clinical status due to a confirmed viral URI Time: 0-12 monthsOther Outcomes
Measure: Percentage of participants who die due to any cause Time: 0-12 monthsDescription: Death due to any cause, hospitalization for myocardial infarction, or hospitalization for ischemic stroke
Measure: Percentage of participants experiencing a major adverse cardiovascular event Time: 0-12 monthsDescription: Major adverse cardiovascular events, hospitalization for acute coronary syndrome, and coronary revascularization (i.e., percutaneous coronary intervention and/or coronary artery bypass graft)
Measure: Percentage of participants experiencing an expanded major adverse cardiovascular event Time: 0-12 monthsMeasure: Percentage of participants who are hospitalized for heart failure Time: 0-12 months
Measure: Percentage of participants who are hospitalized for any reason Time: 0-12 months
Measure: Percentage of participants who have an emergency department visit for any reason Time: 0-12 months